CDKN2A and neoplasm: Both of these lncRNAs have been identified across a number of cancer studies (H19 [51], ANRIL [65, 66]);however, depending on the cancer type, each has functioned as a tumour suppressor (i.e., ANRIL deactivating tumour suppressors CDKN2A/B in cis by three different epigenetic mechanisms [67–69]) and as an oncogene (i.e., H19 acts as a sponge for FOXM1 by absorbing miR-342–3p [70]).